Investor Relations (IR) Questions: Neuralstem Inc CUR
Click here to return to the biotech IRQ Index
Answers received: March 2013
1) When is the last time CUR raised cash through an offering (diluted)?
In September 2012 the company sold 7,000,000 shares of its common stock, offered at $1.00 per share.
2) How much cash (not cash equivalents) does CUR have?
As of December 31, 2012 total cash and cash equivalents was approximately $7,444,000.
3) What and approximately when is the next known catalyst?
˃ CUR has five cell therapy trials planned for 2013.
˃ The two new (NSI-566) U.S. trials will be the ALS Phase II, and the recently FDA-approved Phase I in chronic spinal cord injury.
˃ The company hopes to have agreements with multiple sites for the Phase I chronic spinal cord injury trial in place by the end of the 2nd Quarter and then begin the transplantations.
˃ Internationally, CUR's (NSI-566) ischemic stroke trial is expected to commence in Beijing at BaYi Brain Hospital in the coming weeks, through CUR's subsidiary, Neuralstem China.
˃ A planned ALS combined Phase I/II is expected to take place in Mexico City, pending finalization of a partnership agreement.
˃ Later this month the company (CUR) expects to file an IND for an acute spinal cord injury trial in Seoul, South Korea. The company anticipates conducting this study with CJ CheilJedang.
˃ Regarding NSI-189: Dosing of all patients in the second cohort will be completed this month and, pending FDA approval, CUR will commence dosing the final cohort.
Source: http://finance.yahoo.com/news/neuralstem-announces-2012-financial-results-131500970.html.
The following is a breakdown of CUR's most advanced studies and their anticipated development plan:
PROGRAM: NSI-566 // INDICATION: ALS
STATUS: Phase I completed
PLAN: Anticipated to commence Phase II during the first half of 2013.
PROGRAM: NSI-566 // INDICATION: Chronic Spinal Cord Injury
STATUS: Investigational NDA application approved 1/14/13.
PLAN: Phase I expected to begin during the second quarter 2013.
PROGRAM: NSI-566 // INDICATION: Motor deficits due to ischemic stroke
STATUS: Approved to commence combined Phase I/II clinical trials in China.
PLAN: Anticipated to commence trials during the first quarter of 2013.
PROGRAM: NSI-189 // INDICATION: Major Depressive Disorder
STATUS: Completed Phase Ia, Phase Ib underway, with 2 cohorts having commenced treatment to date.
PLAN: Actively looking to partner development after Phase Ib trial.
Source: Page 4 of the 10-Q filed by CUR on 03/15/2013 and available for download at http://investor.neuralstem.com/phoenix.zhtml?c=203908&p=irol-sec
4) What is CUR's quarterly cash burn?
Currently our monthly cash burn for operations is approximately $780,000. We anticipate that our available cash, expected income and expected proceeds from sales of our securities will be sufficient to finance our current activities at least through December 31, 2013, although certain activities and related personnel may need to be reduced.
Source: Page 11 of the 10-Q filed by CUR on 03/15/2013 and available for download at http://investor.neuralstem.com/phoenix.zhtml?c=203908&p=irol-sec
5) Does CUR have an existing line of credit and if so how much can they draw against it?
At this time CUR does not have a credit facility.
1) When is the last time CUR raised cash through an offering (diluted)?
In September 2012 the company sold 7,000,000 shares of its common stock, offered at $1.00 per share.
2) How much cash (not cash equivalents) does CUR have?
As of December 31, 2012 total cash and cash equivalents was approximately $7,444,000.
3) What and approximately when is the next known catalyst?
˃ CUR has five cell therapy trials planned for 2013.
˃ The two new (NSI-566) U.S. trials will be the ALS Phase II, and the recently FDA-approved Phase I in chronic spinal cord injury.
˃ The company hopes to have agreements with multiple sites for the Phase I chronic spinal cord injury trial in place by the end of the 2nd Quarter and then begin the transplantations.
˃ Internationally, CUR's (NSI-566) ischemic stroke trial is expected to commence in Beijing at BaYi Brain Hospital in the coming weeks, through CUR's subsidiary, Neuralstem China.
˃ A planned ALS combined Phase I/II is expected to take place in Mexico City, pending finalization of a partnership agreement.
˃ Later this month the company (CUR) expects to file an IND for an acute spinal cord injury trial in Seoul, South Korea. The company anticipates conducting this study with CJ CheilJedang.
˃ Regarding NSI-189: Dosing of all patients in the second cohort will be completed this month and, pending FDA approval, CUR will commence dosing the final cohort.
Source: http://finance.yahoo.com/news/neuralstem-announces-2012-financial-results-131500970.html.
The following is a breakdown of CUR's most advanced studies and their anticipated development plan:
PROGRAM: NSI-566 // INDICATION: ALS
STATUS: Phase I completed
PLAN: Anticipated to commence Phase II during the first half of 2013.
PROGRAM: NSI-566 // INDICATION: Chronic Spinal Cord Injury
STATUS: Investigational NDA application approved 1/14/13.
PLAN: Phase I expected to begin during the second quarter 2013.
PROGRAM: NSI-566 // INDICATION: Motor deficits due to ischemic stroke
STATUS: Approved to commence combined Phase I/II clinical trials in China.
PLAN: Anticipated to commence trials during the first quarter of 2013.
PROGRAM: NSI-189 // INDICATION: Major Depressive Disorder
STATUS: Completed Phase Ia, Phase Ib underway, with 2 cohorts having commenced treatment to date.
PLAN: Actively looking to partner development after Phase Ib trial.
Source: Page 4 of the 10-Q filed by CUR on 03/15/2013 and available for download at http://investor.neuralstem.com/phoenix.zhtml?c=203908&p=irol-sec
4) What is CUR's quarterly cash burn?
Currently our monthly cash burn for operations is approximately $780,000. We anticipate that our available cash, expected income and expected proceeds from sales of our securities will be sufficient to finance our current activities at least through December 31, 2013, although certain activities and related personnel may need to be reduced.
Source: Page 11 of the 10-Q filed by CUR on 03/15/2013 and available for download at http://investor.neuralstem.com/phoenix.zhtml?c=203908&p=irol-sec
5) Does CUR have an existing line of credit and if so how much can they draw against it?
At this time CUR does not have a credit facility.